Atossa Genetics (ATOS) Projected to Announce Earnings on Tuesday

Atossa Genetics (NASDAQ:ATOS) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Atossa Genetics to announce earnings of ($1.04) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). On average, analysts expect Atossa Genetics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Atossa Genetics Stock Performance

Shares of ATOS stock traded up $0.12 during mid-day trading on Tuesday, hitting $2.29. 19,280 shares of the stock traded hands, compared to its average volume of 132,585. Atossa Genetics has a twelve month low of $1.70 and a twelve month high of $19.35. The company’s 50-day simple moving average is $2.84 and its 200-day simple moving average is $4.66. The firm has a market cap of $19.72 million, a price-to-earnings ratio of -0.71 and a beta of 1.29.

Analysts Set New Price Targets

Several brokerages recently weighed in on ATOS. Ascendiant Capital Markets decreased their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Rodman & Renshaw initiated coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings downgraded shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Atossa Genetics presently has an average rating of “Hold” and an average target price of $20.33.

Hedge Funds Weigh In On Atossa Genetics

A number of institutional investors have recently bought and sold shares of ATOS. &PARTNERS purchased a new stake in Atossa Genetics during the fourth quarter valued at about $25,000. Hudson Bay Capital Management LP purchased a new position in shares of Atossa Genetics in the second quarter worth approximately $26,000. JPMorgan Chase & Co. increased its position in shares of Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after acquiring an additional 35,474 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares during the period. Finally, XTX Topco Ltd raised its holdings in shares of Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after acquiring an additional 144,412 shares during the period. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.